Australian Clinical Labs
Australian Clinical Labs is a leading provider of pathology services in Australia, offering a comprehensive range of diagnostic testing services. The company operates over 50 NATA-accredited laboratories and more than 1,200 collection centers, serving a diverse clientele. Its commitment to quality and innovation positions it as a key player in the healthcare sector.
Short position
Australian Clinical Labs (ASX:ACL) has 4.39% of its shares on issue reported as short positions as of 5 Oct 2026, or about 8,197,284 shares. Over the past 30 days that figure has fallen 0.43 percentage points, and over 90 days it has fallen 3.17 percentage points. Its highest recorded short interest was 11.19% in July 2024. ACL is classified in the Health Care Equipment & Services industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Australian Clinical Labs (ACL) short interest history
ACL Short Interest History
- 30-day change
- -0.43pp
- 90-day change
- -3.17pp
- 1-year change
- +1.15pp
- All-time high
- 11.19% (July 2024)
- All-time low
- 0.00% (April 2012)
Is ACL heavily shorted?
Not especially: 4.39% short interest is modest by ASX standards, ranking #77 of 799 ASX securities with reported short positions. ASIC requires positions of 0.01% of issued capital or $100,000 (whichever is less) to be reported.
How has ACL's short interest changed recently?
Over the past 30 days Australian Clinical Labs's short interest has been broadly stable, and over 90 days it has fallen 3.17 percentage points. The current level is 4.39% of shares on issue.
What is the highest ACL's short interest has been?
Since 2011, Australian Clinical Labs's short interest peaked at 11.19% in July 2024 and bottomed at 0.00% in April 2012.
Where does this data come from?
All figures are sourced from daily ASIC short position reports, published with a four trading-day (T+4) delay. Shorted aggregates the full history since 2011. See our methodology.